Gen Z and Millennials Have Differing Views on Ozempic
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Gen Z and millennials have radically different views on GLP-1s like Ozempic and how much they want the weight loss and diabetes drugs regulated, according to a new report from GLP-1 prescription weight loss company Levity.
While 40 percent of current and recent GLP-1 (glucagon-like peptide-1) users said the current regulations are fair, 28 percent want fewer rules and 22 percent said there should be more.
But in the millennial age group, users tend to want less regulation, while Gen Z leaned toward more.
Why It Matters
GLP-1s, which are injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity in recent years.
Popular products, including Ozempic, Mounjaro, Wegovy and Zephound, have been a game changer for many Americans who are obese or have type 2 diabetes.
However, stricter FDA rules are now in effect, banning certain compounded GLP-1s and making it more difficult for many Americans to secure the drugs, especially if using it for weight loss reasons.
Ozempic is medicine for adults with type 2 diabetes.
Ozempic is medicine for adults with type 2 diabetes.
Steve Christo - Corbis/Corbis via Getty Images
What To Know
The Gen Z and millennial response to the stricter FDA rules have been notably different, according to Levity.
At 31 percent, millennials were the most likely to favor fewer GLP-1 regulations compared to 19 percent of the group who wanted more.
Gen Z, meanwhile, favored stricter rules at 37 percent, while 32 percent wanted fewer.
"Millennials are more likely to be prescribed a GLP-1 as compared to Gen Z; therefore, it is not surprising that millennials desire less regulation on these drugs," Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek.
"Having said that, the regulatory environment surrounding compounded agents, in general, and compounded GLP-1s, specifically, is not as rigorous as it is for branded and generic drugs. Therefore, compounded drugs carry unknown risks that more regulated medications do not."
Because semaglutide is no longer on the FDA shortage list, compounding it can carry legal risks. Already, the effects are being felt, as 17 percent of GLP-1 users said it has become harder to get their medication since the FDA tightened rules on compounded semaglutide, Levity reported.
There was also a difference in how the generations viewed their use of the drugs.
While 75 percent of GLP-1 users believed they'll still be on their treatment plan a year from now, Gen Z was the least likely to think so, at 58 percent.
What People Are Saying
Board-certified endocrinologist Dr. Caroline Messer told Newsweek: "Millennials, many of whom are now managing midlife weight and metabolic health concerns, may see GLP-1s as a practical tool and want fewer barriers. Gen Z, meanwhile, is generally more wary of long-term unknowns, hence leaning toward more safeguards. Broadly, Americans are divided but lean toward keeping current regulations."
Richard Frank, MD, MHSA, and chief medical officer at Vida Health, told Newsweek: "From a business perspective, limiting access to compounded drugs when branded drugs are available protects the drug companies' patents. This protection provides the financial incentive for drug companies to develop innovative new therapies."
What Happens Next
The long-term effects of GLP-1 medication use are so far unclear. A recent study discovered a new link between taking GLP-1 drugs and elevated risk of pancreatitis and kidney conditions, including kidney stones.
And GLP-1 medications have also been associated with a higher risk of digestive problems, including nausea, vomiting, diarrhea and even stomach paralysis in rare cases.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Novo Nordisk Shares Rise on U.S. Approval of Wegovy for Liver Disease
Novo Nordisk (NVO, Financials) shares climbed nearly 5% Monday after the U.S. Food and Drug Administration granted accelerated approval for its weight-loss drug Wegovy to treat metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis. Warning! GuruFocus has detected 1 Warning Sign with NVO. The approval makes Wegovy the first GLP-1 therapy cleared for MASH, a progressive liver condition affecting about 5% of U.S. adults, according to the American Liver Foundation. The drug was approved for use alongside a reduced-calorie diet and increased physical activity. Novo Nordisk said the decision was supported by the first phase of its ESSENCE trial, which showed Wegovy patients had statistically significant improvements in liver fibrosis compared to placebo. About 63% of participants receiving Wegovy achieved resolution of steatohepatitis without worsening fibrosis, compared with 34% in the placebo group. More than one-third of Wegovy patients also saw improvement in fibrosis without worsening steatohepatitis, versus 22% on placebo. The second phase of the trial is expected in 2029. The company said Wegovy is immediately available in the U.S. for MASH. The only other FDA-approved treatment for the disease is Madrigal Pharmaceuticals' (MDGL, Financials) Rezdiffra, cleared in 2024. Novo Nordisk shares were up 5.46% in London trading as of 10:43 a.m. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
15 minutes ago
- Newsweek
Mom Shares Signs in Daughter That Pointed To 'Devastating Diagnosis' Ahead
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A Canadian mom has shared a video of her daughter as a toddler and the signs in her behavior that pointed to what lay ahead. In a clip posted to TikTok under the handle @mandaburritt, Amanda Burritt, from Calgary, Alberta, posted a compilation of clips from when her daughter Emma was a toddler. "Signs from 6-12 months that led us to getting our daughter's devastating diagnosis," a caption accompanying the video reads. Burritt told Newsweek: "When Emma was around 8 months old, I started getting a little concerned about her development but was brushed off by our doctor stating kids develop at their own pace." It is normal for parents to worry about whether their children are hitting all of their developmental milestones. In 2022, a survey of 2,000 parents of children ages 3 and under, conducted by OnePoll on behalf of VtECH, found 59 percent worry their babies are not hitting developmental milestones. Burritt had more concerns than most new moms and dads, though. "Emma wasn't sitting on her own, crawling or moving around at all," she said. The video posted online offers a glimpse of how Emma behaved during that period. What Burritt saw on a day-to-day basis was enough to convince her to take action. It started with her self-referring Emma to Early Intervention in the hopes that, whatever issue her daughter had, they would be able to help her catch up with her peers. However, by the age of 1, little had changed. "She was still behind in all areas and had a lack of awareness of her environment," Burritt said. At this point, their doctor began to express similar concerns, and Emma was referred to British Columbia Children's Hospital where further tests were conducted. Even then, Emma's condition did not become immediately clear. "The only thing they found was her MRI report, which said she had insufficient myelination of the optic radiations." With no other explanations, it was decided that Emma would need to undergo Whole Exome sequencing, in order to find out what was going on. Seven months later, Burritt received Emma's official diagnosis: KIF1A-associated neurological disorder. KAND is a rare, degenerative neurological disorder that is caused by mutations in the KIF1A gene. This is responsible for producing the KIF1A protein, which plays a key role in the healthy development of brain cells and nerve fibers. Amanda Burritt's daughter Emma plays on the floor at home as a baby. Amanda Burritt's daughter Emma plays on the floor at home as a baby. TikTok/mandaburritt/thelifeofemmabean These mutations can impact the nervous system, resulting in developmental delays such as the ones Burritt witnessed with her daughter Emma and a variety of neurological problems ranging from issues with vision to intellectual disability. Burritt was told her daughter's condition was "ultra rare," with around 600 cases diagnosed worldwide. There is no specified treatment or cure for KAND as symptoms can different greatly from patient to patient. However, those caring for someone with the condition can take steps to assist in areas of their school, work or social life. Emma is now 6, and Burritt says she has yet to make much in the way of "significant gains" in the years since that TikTok video was filmed. "Emma is blind, nonverbal, nonmobile, has little to no balance and very poor motor planning," Burritt said. "She is fully dependent on us for everything and requires 24/7 care." That hasn't stopped Burritt from pouring everything she has into getting her daughter the best-possible care. "We have done everything in our power to ensure she gets the best therapies and opportunities to thrive," Burritt said. "We moved provinces for better resources available, leaving behind our entire lives. I gave up my career as a nurse so that I could give Emma 100 percent of my attention, and bringing her to therapy became my full-time job." Burritt and her family have traveled thousands of miles to get Emma the best therapy. She even raised over $40,000 last year to pay for a robotic walker to help strengthen her daughter's legs and stimulate pathways in her brain. In the meantime, Emma attends a specialized school for disabled children where she undergoes daily therapies as part of her day-to-day learning and even enjoys adaptive horseback riding aimed at improving core strength. Through all of this, Burritt has never given up hope, buoyed in part Emma's smile and eternal sunshine spirit. "Over the years, she has spent hundreds and hundreds of hours working so hard fighting against this disease and, despite her challenges, she remains the happiest little girl," Burritt said. "She loves therapy and, for that, I'm grateful. Although the progress has been slow, it's still progress, and we are thankful she hasn't regressed. She has gained a lot of strength overall, and I'm beyond proud of her." Emma, now, aged 6, smiles outdoors. Emma, now, aged 6, smiles outdoors. TikTok/mandaburritt Burritt posts videos about Emma to TikTok and also Instagram, where her content is shared under the handle @thelifeofemmabean. In doing so, Burritt said she hopes to raise awareness about KAND and help other families get the treatment they need as soon as possible. "We recently attended the Kif1a conference in Boston and a huge factor in how small our Kif1a community is due to genetic testing not being accessible or available," Burritt said. "Emma's disease shares a lot of similarities to cerebral palsy, so lots of kids get misdiagnosed with that, prior to receiving their genetic testing. I think it's important for people to fight for genetic testing if there are no clear reasons their child has delays." Burritt would always encourage parents to "listen to your gut" when it comes to your own child's development. Doing so will allow them to get the help they need, she said, should they need it, as soon as possible.
Newsweek
15 minutes ago
- Newsweek
Number of Younger Mothers Set To Fall Dramatically Amid Population Fears
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The share of births to women under 25 is set to fall in every world region amid ongoing birth rate fears, new graphs show. In Northern America, births from women between the ages of 15 and 24 are projected to make up 12 percent of births by 2100, down from about 23 percent this year and 45 percent in 1950. This is according to the Pew Research Center's analysis of the U.N. Population Division's 2024 Revision of World Population Prospects. Newsweek previously reported on the trend in mothers having children at consistently older ages, with those between 15 and 19 seeing the most consistently steep fall in the past 50 years. Pew Research Center graphs showing how the share of births for women under 25 is set to decrease. Pew Research Center graphs showing how the share of births for women under 25 is set to decrease. Pew Research Center Why It Matters The projected drop in births among women under 25 signals sustained shifts in family formation that could accelerate population aging and shrink future workforces in many countries, pressuring pension systems and public services. What To Know Pew Research Center found that the share of births to women younger than 25 was projected to decline in every global region, reflecting a worldwide shift toward later childbearing and smaller family size. In Europe, this share is set to drop even lower than in Northern America—from 15 percent in 2025 to 9 percent in 2100, down from 35 percent in 1950. Meanwhile, in Latin America and the Caribbean, where births to women between the ages of 15 and 24 make up about 39 percent in 2025, this age group's share is predicted to drop to 17 percent in 2100. Africa, where the fertility rate is generally higher than in the rest of the world, births to women under the age of 25 make up about 41 percent—as they did in 1950—and are projected to drop to 20 percent. Demographers and economists have attributed lower fertility to a mix of factors, including delayed partnership and childbearing, greater labor force participation by women, improved access to contraception, and cultural shifts that places less centrality on parenthood for life plans. "No one factor can really explain the reductions," said Claire Brindis, a co-director of the Adolescent and Young Adult Health National Research Center at the University of California, San Francisco, citing a lower level of sexual activity among teenagers, a higher level of contraceptive use and wider social changes. She previously told Newsweek, "We have to give young people a lot of credit" for the dramatic drop in teen pregnancies. A major challenge to having children is financial security. The 2008 financial crisis—with its effect on housing, inflation and pay—was a major contributor to why people delayed having children, had fewer of them or had none at all. While some policymakers have proposed incentives such as lump‑sum "baby bonuses" or expanded parental leave, several researchers have urged broader, longer-term supports—such as affordable child care, paid leave and gender‑equal domestic policies—to influence fertility decisions more sustainably. What People Are Saying Claire Brindis, a co-director of the Adolescent and Young Adult Health National Research Center at the University of California, San Francisco, previously told Newsweek: "We should recognize that there continues to be segments who are more likely to be at risk—young people who are poor or low income, those who live in rural communities, with less education, and with less hope for economic opportunities continue to be more vulnerable. "The risks are that we don't continue to invest in young people across all groups, and especially women, if education opportunities are shut off, if economic options (as an alternative to going to college), if student loans are eliminated or more difficult to get, if families have more economic struggles, if access to birth control or other social support services, for example, many of these positive trends can evaporate." Phillip B. Levine, an economist from Wellesley College in Massachusetts, who recently conducted a study on the cultural reasons behind the birth rate decline, previously told Newsweek: "Policies like parental leave, child care subsidies, baby bonuses, etc. are much easier to implement and have the potential to affect fertility more rapidly, if they were effective. Changing the social conditions that encourage family formation is more difficult and takes longer to accomplish." What Happens Next Many governments have made addressing declining birth rates a priority. In the U.S., President Donald Trump's administration has explored giving women a "baby bonus" of $5,000, according to an April New York Times report. Lawmakers have also looked at making childbirth free for privately insured families and tying states' transportation funding to their birth and marriage rates.
